Produção Nacional
Revisado por pares
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
2023; Elsevier BV; Volume: 21; Issue: 5 Linguagem: Inglês
10.1016/j.clgc.2023.03.006
ISSN1938-0682
AutoresMatteo Santoni, Francesco Massari, Zin Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindřich Kopecký, Jakub Kucharz, Sebastiano Buti, Alessia Salfi, Thomas Büttner, Ugo De Giorgi, Ravindran Kanesvaran, Ondřej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, María T. Bourlon, Sarah Scagliarini, Javier Molina‐Cerrillo, Gaetano Aurilio, Marc Matrana, Renate Pichler, Carlo Cattrini, Tomáš Büchler, Emmanuel Seront, Fabio Calabrò, Álvaro Pinto, Rossana Berardi, Anca Zgură, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Roubini Zakopoulou, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Ilaria Zampiva, Carlo Messina, Zsófia Kürönya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Ilaria Catalini, Fernando Sabino Marques Monteiro, Rodolfo Montironi, Nicola Battelli, Mimma Rizzo, Camillo Porta,
Tópico(s)Urinary and Genital Oncology Studies
ResumoObesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC).Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival.A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002).Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.
Referência(s)